A View LCS vs ElucidVivo A.3
AI Verdict
Choose A View LCS if…
Choose A View LCS if your primary need is a comprehensive, multi-faceted thoracic assessment from a single low-dose CT scan. This tool is ideal for lung cancer screening programs that also require automated quantification of emphysema and coronary artery calcification for broader patient risk stratification and reporting.
View A View LCS →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your focus is on detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This tool is best suited for cardiologists and vascular surgeons who need to stratify atherosclerosis patients, understand lesion-level plaque characteristics, and optimize treatment decisions based on precise measurements of plaque components like LRNC and calcifications.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | ElucidVivo A.3 |
|---|---|---|
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
A View LCSAVIEW LCS emphasizes an automated, 'Zero-Click' workflow and effortless report generation, which streamlines tasks and enhances efficiency for medical professionals. It also features a user-friendly 3D viewer for improved communication and understanding. While ElucidVivo A.3 offers detailed visualizations, AVIEW LCS's focus on automation and award-winning UX/UI in related products suggests a higher degree of usability and workflow integration.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 provides highly specialized, histology-validated quantitative analysis of arterial plaque composition and stability, including the derivation of fractional flow reserve (FFRct), which offers profound insights for atherosclerosis patient stratification and treatment decisions. It has demonstrated a 40% improvement in predictive accuracy for major adverse neurologic events compared to stenosis alone. While AVIEW LCS offers broad screening for multiple thoracic conditions, ElucidVivo A.3's depth of analysis, ground-truth validation, and direct impact on critical cardiovascular interventions give it a superior clinical value in its specific domain.
Pricing & Value
TieBoth tools require direct contact for pricing, lacking public transparency regarding specific costs. While AVIEW LCS provides general pricing models (one-off payment, subscription based on installations/users), neither offers sufficient detail to conduct a head-to-head comparison of their financial value propositions.
Enterprise Readiness
A View LCSAVIEW LCS explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), alongside diverse deployment options including cloud, hybrid, local hardware, and virtualized solutions. This comprehensive approach to compliance and deployment flexibility demonstrates superior readiness for integration into various enterprise IT environments. ElucidVivo A.3's compliance is implied, and its deployment options are less explicitly detailed.
Innovation
ElucidVivo A.3ElucidVivo A.3 stands out with its histology-validated AI for quantitative analysis of arterial plaque composition and stability, including the unique ability to derive FFRct from CT angiography. It is the first FDA-cleared non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, representing a significant advancement in cardiovascular diagnostics. While AVIEW LCS's '3-in-1' comprehensive thoracic analysis and CT kernel conversion are innovative, ElucidVivo A.3's ground-breaking, histology-validated plaque characterization offers a more profound and specific leap in clinical understanding and personalized treatment.
Support & Docs
A View LCSCoreline Soft, the company behind AVIEW LCS, explicitly lists a 'Customer Service Team' with a dedicated email address and provides access to various catalogs and technical brochures. This indicates a more structured approach to customer support and documentation. Elucid Bioimaging does not provide comparable explicit details regarding its support structure or documentation availability in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | ElucidVivo A.3 |
|---|---|---|
| Name | A View LCS | ElucidVivo A.3 |
| Company | Coreline Soft Co. | Elucid Bioimaging |
| Description | AVIEW LCS by Coreline Soft is an FDA-cleared AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. | ElucidVivo A.3 by Elucid Bioimaging is an FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Primary Focus | Comprehensive thoracic CT analysis (lung cancer screening, emphysema, coronary artery calcification) | Quantitative analysis of arterial plaque composition and stability from CT angiography |
| Key Features (Examples) | Automated lung nodule detection and classification, Emphysema analysis and quantification (LAA), Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass) | AI-powered quantitative analysis of arterial plaque, Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and ElucidVivo A.3.